Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.

@article{Amann2010GeneticAP,
  title={Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.},
  author={Joseph M. Amann and J. W. Lee and Heinrich Roder and Julie Brahmer and Adriana Vilchis Gonzalez and Joan Hoff Schiller and David Paul Carbone},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2010},
  volume={5 2},
  pages={169-78}
}
INTRODUCTION Serum proteomics and mutations in the epidermal growth factor receptor (EGFR) and KRAS have been associated with benefit after therapy with EGFR-targeted therapies in non-small cell lung cancer, but all three have not been evaluated in any one study. HYPOTHESIS Pretreatment serum proteomics predicts survival in Western advanced non-small cell lung cancer patients with wild-type EGFR and independent of KRAS mutation status. METHODS We analyzed available biospecimens from Eastern… CONTINUE READING

From This Paper

Topics from this paper.